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Introduction: Bronchioloalveolar carcinoma (BAC) is a subtype of
adenocarcinoma of the lung with unique pathological, clinical, and
molecular characteristics.
Methods: This consensus conference group reviewed studies per-
formed specifically in BAC and data from patients with BAC who
were included in clinical trials of all non–small-cell lung cancer
(NSCLC) subtypes.
Results: Although BAC as defined by the World Health Organiza-
tion represents less than 5% of adenocarcinomas, as many as 20% of
adenocarcinomas have BAC features. These latter tumors are more
likely to have mutations in the epidermal growth factor receptor
(EGFR) gene and to be sensitive to the EGFR tyrosine kinase
inhibitors gefitinib and erlotinib. Although most patients are men
and have a history of smoking cigarettes, proportionally more are
women and never smokers. Patients with BAC are routinely treated
with drugs and regimens appropriate for patients with all subtypes of
adenocarcinoma of the lung; four studies have been performed
specifically in this disease.
Conclusions: There is insufficient evidence to confirm or refute the
assertion that the sensitivity of BAC to chemotherapy is different
from that of other lung cancer histologic types. The unique clinical
and molecular characteristics associated with BAC led this panel to
conclude that future clinical trials should be designed specifically for
persons with BAC. Recommendations for trial design and research
questions are proposed.
Key Words: Adenocarcinoma, Bronchioloalveolar carcinoma,
Epidermal growth factor receptor, Gefitinib, Erlotinib.
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Bronchioloalveolar carcinoma (BAC) may be distinguishedfrom other adenocarcinomas of the lung by unique his-
tology, radiology, molecular biology, and clinical course. It is
thought that the course of patients with BAC is more indolent
than in persons with other non–small-cell lung cancer
(NSCLC) histologies. Although “pure” BAC is defined ex-
plicitly by the World Health Organization (WHO),1 there are
many more patients whose adenocarcinomas have features of
BAC, making the histologic classification of such tumors
uncertain.2 Several clinical trials have been performed spe-
cifically in patients with BAC, based on the notion that these
tumors may be somewhat less sensitive to standard chemo-
therapy and that the biology of BAC differs from that of other
adenocarcinomas.
MATERIALS AND METHODS
This conference group reviewed results of patients with
BAC included in trials studying patients with NSCLC in
general and five studies designed specifically for persons with
BAC, testing paclitaxel, gefitinib, and erlotinib. Local treat-
ment approaches are also outlined here, including inhala-
tional therapy with investigational anticancer agents. The
conference group made recommendations for clinical trial
design and further research in BAC.
RESULTS
Results in Patients with BAC Included in ECOG
Trial 1594 in Patients with Advanced NSCLC
The Eastern Cooperative Oncology Group (ECOG)
studied four platinum-based regimens as initial therapy for
patients with NSCLC.3 This study included 1163 patients, 17
of whom were classified as having BAC by the investigator.
The response rate in patients with BAC was 6% compared
with 20% for patients with other types of NSCLC. Median
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survival for persons with BAC was 12 months compared with
8 months overall.
Trials Conducted Specifically in Patients with
BAC
Paclitaxel by 96-hour Infusion for Patients with
BAC (SWOG9714)
The Southwest Oncology Group (SWOG) conducted
the first prospective trial for patients with BAC.4 Patients in
this trial had ECOG performance status 0 to 2 and stage
IIIB/IV BAC as determined by the treating institution. All 58
patients received paclitaxel 35 mg/m2/day continuously in-
fused for 96 hours every 21 days. The partial response rate
was 14%. Median overall survival was 12 months, and the
3-year survival rate was 13%. Because of a high treatment-
related death rate (9%, 5/58), this regimen was not pursued.
However, this trial demonstrated the feasibility of conducting
prospective trials in patients with BAC in a cooperative group
setting and established benchmarks for future studies.
Paclitaxel by 3-hour Infusion for Patients with
BAC (EORTC 08956)
The European Organization for Research and Treat-
ment of Cancer Lung Cancer Group studied a 3-hour pacli-
taxel infusion in patients with stage IIIB/IV BAC.5 Nineteen
patients received paclitaxel 200 mg/m2 every 21 days. Two
partial responses were confirmed (response rate of 11% (95%
CI, 1 to 35%). The median survival was 9 months, and the
1-year survival rate was 35% (95% CI, 14 to 56%). The study
was terminated because of a low response rate.
Gefitinib (Iressa) for Patients with BAC
(SWOG 0126)
SWOG S0126 evaluated 500 mg of gefitinib per day.6
The study was undertaken based on the detection of epider-
mal growth factor receptor (EGFR) protein in BAC tumors
collected from S9714, the activity seen in patients with
NSCLC in phase I trials of gefitinib, and reports of rapid and
durable responses in patients with BAC.7,8 This study en-
rolled 55 patients with eligibility identical to the preceding
S9714 trial along with 35 previously treated patients. All had
performance status of 0 to 2 and stage IIIB/IV BAC as
determined by the treating institution. Approximately one
third of patients had a dose reduction to 250 mg based on
toxicities, and 11% discontinued therapy. Three patients de-
veloped increasing pulmonary infiltrates and hypoxemia re-
quiring treatment with steroids, antibiotics, and supplemental
oxygen after discontinuing gefitinib. Each of these patients
died of what was possibly treatment-related interstitial lung
disease, although disease progression, infection, or other
causes may have contributed. Among patients with measur-
able disease, gefitinib response rates (RECIST) were 19 and
9% for chemo-naı¨ve and chemo-pretreated patients, respec-
tively. Complete responses were seen. The median survival of
untreated patients was 12 months, similar to that in SWOG
9714. Several patients had progression-free survival of more
than a year, something not observed with paclitaxel. The
survival at 2 and 3 years was 38 and 23%, an improvement on
the 29 and 13% seen in S9714. Patients with nonmucinous
BAC had superior survival on gefitinib compared with those
with the same histologic features treated with paclitaxel on
protocol S9714 discussed above.9 Increased EGFR gene copy
number detected by fluorescence in situ hybridization was
associated with improved survival.10 Correlations of clinical
outcomes with EGFR protein expression measured by immu-
nohistochemistry and EGFR mutations are ongoing.
Erlotinib (Tarceva) for Patients with BAC
During the early testing of erlotinib, dramatic responses
were observed in patients with BAC. To follow up on this
lead, four centers undertook a phase II trial of erlotinib 150
mg daily in patients with BAC—both “pure BAC” as defined
by the WHO and adenocarcinoma with BAC features.2,11 A
total of 159 patients with stage IIIB or IV inoperable NSCLC
had central review of biopsy specimens. BAC was identified
in 66% of submitted specimens. Like the SWOG studies,
pathological eligibility was determined by the reading from
the pathology department where the patient was treated, not
by central review. One hundred one patients were treated;
67% of the patients were women, and 22% had previously
received chemotherapy. Central pathology review showed
that 12% were “pure BAC” and that 88% had adenocarci-
noma with BAC features. Twenty-five percent of the patients
had never been smokers. A final report is planned for the first
half of 2006.
Erlotinib treatment led to partial responses (RECIST
criteria) in 20 of the 84 patients evaluated at the time of the
report (24%; 95% CI, 16 to 34%). The partial response rate
was 40% in never smokers and 19% in current or former
smokers. The 1-year survival rate rfor all patients was 58%;
the median survival rate has not yet been determined. There
was one case of interstitial lung disease resulting in treat-
ment-related death. EGFR exons 18 to 24 have been se-
quenced in 19 tumor specimens to date. Among nine patients
with partial responses, six had EGFR mutations, two with
deletions in exon 19, and four had substitution mutations in
exon 21 (L858R).12 None of the 10 patients who did not have
partial responses had a mutation in EGFR exons 18 to 24. The
trial closed to accrual in April 2005. Studies of EGFR protein
expression, EGFR copy number, sequencing of EGFR exons
19 and 21, and sequencing of KRAS exon 2 will be obtained
from all patients with tumor tissue available. A final report is
planned for the first half of 2006.
Trial of gefitinib for patients with Pneumonic-Type
Adenocarcinoma
This prospective French Thoracic Oncology Intergroup
30-center phase II study (IFCT 04-01) opened in May 2004 to
evaluate gefitinib 250 mg daily as a first-line therapy for
patients with nonresectable, pathologically proven, pneumo-
nic-type adenocarcinoma as defined by Wislez et al.13 This
group includes adenocarcinomas with both mixed-invasive
and BAC-predominant subtypes. Interim results were re-
ported at the International Association for the Study of Lung
Cancer meeting in Barcelona, Spain in July 2005.14 Objective
responses were documented in four of 24 patients reported
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(17% observed rate, 95% CI, 5 to 37%). Tissue will be
analyzed for expression of EGFR, HER2, P-AKT, and
MAPK as well as mutations in KRAS codon 12 and EGFR
exons 18 to 21. A final report on 90 patients is planned for the
first half of 2006.
Other Strategies
Adenovirus P53 Administered by
Bronchioloalveolar Lavage in Patients with BAC
Because BAC is characterized by thin sheets of tumor
cells growing along the airways, agents delivered by inhala-
tion should have direct access to the tumor. A phase I study
of p53 gene transfer using an adenovirus vector (Ad-p53;
RPR/INGN 201) delivered via bronchioloalveolar lavage
(BAL) to involved lobes of the lung was conducted at the
University of Wisconsin and Vanderbilt University.15 Treat-
ments consisted of two BAL at the same dose level given 2
weeks apart to a single involved lobe. Additional treatment to
all involved lobes was allowed if initial treatments were
tolerated. The initial dose was 2  109 viral particles per
dose, escalated in 10-fold increments. Among 14 patients
registered, grade 4 pulmonary toxicity was noted at the 2 
109 dose level. Two additional patients at this level did not
suffer a dose-limiting toxicity. After the completion of two
cycles, pathologic response was noted on rebiopsy in two
patients, four of nine patients showed improved diffusing
capacity, and four of 11 had symptomatic improvement.
Autologous Antitumor Vaccine GVAX (CG8123)
GVAX (CG8123) (Cell Genesys, Inc.) is a GM-CSF
gene-modified autologous tumor cell vaccine that has shown
antitumor activity in patients with NSCLC and, specifically,
BAC.16,17 Despite these reports, no trials of this construct are
planned for patients with BAC.
Inhalational Therapy: Interferon-, Doxorubicin,
Cisplatin, and Indomethacin
A number of phase II trials and case reports of inhaled
therapy have been described, with endpoints of tumor control
and palliation of bronchorrhea. Ten patients with locally
advanced BAC were treated with interferon-alpha as an
inhaled aerosol with initial doses from 1 to 10 million units
three times weekly and escalated to 20 million units daily.18
No symptomatic or radiographic responses were seen. Aero-
solized doxorubicin has been administered to patients with
primary and secondary pulmonary malignancies, including
six with NSCLC and at least one with BAC. Efficacy data
have not yet been reported.19
Bronchorrhea: A Defining Symptom of BAC
Bronchorrhea, defined as the production of sputum of
100 ml/day, is a defining symptom of BAC. Seen in about
5% of patients, bronchorrhea causes substantial discomfort.
Successful treatment of BAC eliminates this condition. A
variety of treatments directed at this symptom have been
studied, including inhaled indomethacin,20,21 oral and inhaled
corticosteroids,22 and macrolide antibiotics.23,24 Gefitinib in-
hibits mucin production25 and decreases bronchorrhea.26–29
Response Assessment in BAC Trials
Because of the diffuse nature of the pulmonary lesions
often characteristic of BAC, some investigators have sug-
gested that standard methods for response assessment may be
inadequate for phase II trials conducted specifically in pa-
tients with BAC. Despite these concerns, the current standard
of care includes patients with BAC in trials of NSCLC in
general and routinely employs standard bidimensional or
unidimensional response assessment. In addition, all four
multicenter phase II trials completed exclusively in patients
with BAC used standard criteria and reported no difficulties
assessing response by both bidimensional4,5 and unidimen-
sional6,30 methods of assessment.
DISCUSSION
Consensus Recommendations
Y Because BAC represents a subtype of lung adeno-
carcinomas with unique clinical characteristics and
molecular profile, studies specifically designed for
this illness are warranted.
Y The diagnosis of “pure” BAC requires a histologic
specimen from the lung.
Y A precise histologic classification of all NSCLC is
needed.
Y For clinical trials testing systemic therapies for
activity in BAC, a histologic specimen and confir-
mation by central pathologic review are manda-
tory.
Y For clinical trials testing systemic therapies for
NSCLC in general, although histologic confirma-
tion is favored, the use of either histology or
cytology with a mandated central review is an
acceptable alternative.
Y Any feature of BAC in a pathologic specimen
would qualify a patient for BAC-specific treatment
or trials.
Y If clinical features suggest a diagnosis of BAC (e.g.,
bronchorrhea, pneumonic consolidation, multifocal
disease, visually normal bronchoscopy, etc.), but ini-
tial pathological testing is inconclusive, additional
histological evaluation is warranted.
Y A detailed cigarette-smoking history should be
determined in all NSCLC patients. The minimum
information necessary would classify people as
current, former (stopped more than 1 year ago), or
never smokers (fewer than 100 lifetime cigarettes).
Y There is insufficient evidence to confirm or refute
that the sensitivity of BAC tumors to chemother-
apy is different from that of other types of NSCLC.
Y Standard bidimensional (WHO, SWOG) or unidi-
mensional (RECIST) methods of response assess-
ment can be used in phase II trials conducted in
persons with BAC.
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Y Phase II trials have demonstrated that gefitinib and
erlotinib have activity in BAC patients when given
as initial treatment and after chemotherapy.
Y In phase II trials of BAC patients receiving sys-
temic therapies, the observed survival appears
longer than in studies of NSCLC patients.
Y Investigational therapy is acceptable at any point
in the course of advanced BAC.
Y Bronchorrhea is a defining symptom of BAC. It is
best managed by effective treatment of BAC.
Research Areas
• A trial of initial gefitinib or erlotinib, then a platinum-
based doublet versus an initial platinum-based doublet, and
then gefitinib or erlotinib
• Exploration of the use of gefitinib and erlotinib both before
and after surgery
• Trials of BAC-specific targeted therapies must include
determination of molecular correlates for the target of
interest
• Special areas to be addressed in clinical trials of systemic
therapies in BAC:
• Central pathology review
• Response assessment
• Smoking history
• Prior and comorbid pulmonary diseases.
• Proposed or in-progress studies:
• Phase II trial of weekly bortezomib (Velcade) as first- or
second-line treatment (conducted by the California Can-
cer Consortium)
• Phase II trial of twice-weekly bortezomib (Velcade) as
first- or greater-line treatment (conducted by Millennium
Pharmaceuticals)
• Phase II trial of pemetrexed (Alimta) as first- or second-
line treatment (conducted by SWOG)
• Phase II trial of cetuximab (Erbitux) as first- or second-
line treatment (conducted By ECOG).
• Phase II IFCT 05-04 trial: effect of an early therapeutic
permutation on the tumoral control of patients receiving
in the first line a specific inhibitor of tyrosin kinase of
EGFR (erlotinib) or a taxane-based chemotherapy (pac-
litaxel  carboplatin) for the treatment of nonresectable
adenocarcinoma with bronchioloalveolar features.
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